Plus Capital Surpluse vs Good Will Analysis

PSTV Stock

USD 1.34 0.05 3.88%

Plus Therapeutics financial indicator trend analysis is much more than just breaking down Plus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Plus Therapeutics is a good investment. Please check the relationship between Plus Therapeutics Capital Surpluse and its Good Will accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Capital Surpluse vs Good Will

Capital Surpluse vs Good Will Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Plus Therapeutics Capital Surpluse account and Good Will. At this time, the significance of the direction appears to have pay attention.

The correlation between Plus Therapeutics' Capital Surpluse and Good Will is -0.83. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Good Will in the same time period over historical financial statements of Plus Therapeutics, assuming nothing else is changed. The correlation between historical values of Plus Therapeutics' Capital Surpluse and Good Will is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Plus Therapeutics are associated (or correlated) with its Good Will. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Good Will has no effect on the direction of Capital Surpluse i.e., Plus Therapeutics' Capital Surpluse and Good Will go up and down completely randomly.

Correlation Coefficient

-0.83

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Capital Surpluse

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Most indicators from Plus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 9.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.09) in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	419K	712K	628K	968.9K
Cost Of Revenue	66K	712K	9.7M	10.2M

Depreciation And Amortization Cost Of Revenue

Plus Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable	Common Stock Total Equity	Property Plant And Equipment Gross
Total Assets		0.94	0.43	0.17	0.72	0.72	-0.51	0.85	0.86	0.85	-0.47	0.46	-0.45	0.08	0.67	0.29	0.69	0.7	-0.02	0.02	0.15	0.6	0.34	0.5	0.6	-0.69
Short Long Term Debt Total	0.94		0.19	0.43	0.55	0.55	-0.58	0.87	0.9	0.71	-0.35	0.52	-0.41	0.17	0.77	0.38	0.76	0.76	-0.23	-0.09	0.22	0.59	0.24	0.42	0.61	-0.63
Total Stockholder Equity	0.43	0.19		-0.2	0.3	0.3	-0.37	0.03	-0.04	0.32	-0.24	0.0	-0.05	-0.07	0.29	0.15	0.04	0.21	0.16	0.23	0.04	0.3	0.18	0.23	0.26	-0.31
Net Debt	0.17	0.43	-0.2		-0.5	-0.5	-0.41	0.12	0.24	-0.3	0.41	0.46	-0.05	0.17	0.79	0.54	0.24	0.52	-0.37	-0.15	0.4	0.31	-0.39	-0.04	0.38	-0.08
Cash	0.72	0.55	0.3	-0.5		1.0	-0.09	0.72	0.68	0.97	-0.71	0.09	-0.35	-0.02	-0.02	-0.13	0.5	0.23	0.09	0.01	-0.14	0.23	0.58	0.46	0.2	-0.56
Cash And Short Term Investments	0.72	0.55	0.3	-0.5	1.0		-0.1	0.72	0.68	0.97	-0.71	0.09	-0.35	-0.02	-0.02	-0.13	0.5	0.23	0.09	0.01	-0.14	0.23	0.58	0.46	0.2	-0.56
Common Stock Shares Outstanding	-0.51	-0.58	-0.37	-0.41	-0.09	-0.1		-0.39	-0.24	-0.2	0.15	-0.16	-0.28	-0.5	-0.62	-0.37	-0.45	-0.58	0.33	0.25	-0.27	-0.38	-0.19	0.16	-0.39	0.11
Non Current Liabilities Total	0.85	0.87	0.03	0.12	0.72	0.72	-0.39		0.89	0.81	-0.57	0.15	-0.47	0.31	0.47	0.06	0.73	0.71	-0.13	-0.27	-0.19	0.57	0.5	0.25	0.58	-0.57
Total Liab	0.86	0.9	-0.04	0.24	0.68	0.68	-0.24	0.89		0.81	-0.4	0.51	-0.48	0.05	0.54	0.21	0.7	0.62	-0.11	-0.12	0.13	0.49	0.27	0.49	0.51	-0.66
Total Current Assets	0.85	0.71	0.32	-0.3	0.97	0.97	-0.2	0.81	0.81		-0.64	0.24	-0.43	0.02	0.2	0.0	0.63	0.41	0.08	-0.02	-0.06	0.37	0.51	0.5	0.35	-0.65
Other Current Liab	-0.47	-0.35	-0.24	0.41	-0.71	-0.71	0.15	-0.57	-0.4	-0.64		0.23	0.11	-0.28	0.03	-0.02	-0.24	-0.2	0.17	0.25	0.21	-0.07	-0.97	-0.07	-0.07	0.15
Total Current Liabilities	0.46	0.52	0.0	0.46	0.09	0.09	-0.16	0.15	0.51	0.24	0.23		-0.15	-0.37	0.53	0.53	0.3	0.19	0.05	0.37	0.81	0.1	-0.37	0.59	0.11	-0.33
Property Plant And Equipment Net	-0.45	-0.41	-0.05	-0.05	-0.35	-0.35	-0.28	-0.47	-0.48	-0.43	0.11	-0.15		0.41	-0.22	-0.01	-0.25	-0.19	-0.23	-0.38	0.31	-0.26	0.04	-0.61	-0.23	0.73
Retained Earnings	0.08	0.17	-0.07	0.17	-0.02	-0.02	-0.5	0.31	0.05	0.02	-0.28	-0.37	0.41		0.17	0.02	0.45	0.51	-0.32	-0.92	-0.3	0.18	0.47	-0.8	0.21	0.4
Non Current Assets Total	0.67	0.77	0.29	0.79	-0.02	-0.02	-0.62	0.47	0.54	0.2	0.03	0.53	-0.22	0.17		0.55	0.43	0.8	-0.2	-0.08	0.35	0.63	-0.08	0.2	0.66	-0.41
Non Currrent Assets Other	0.29	0.38	0.15	0.54	-0.13	-0.13	-0.37	0.06	0.21	0.0	-0.02	0.53	-0.01	0.02	0.55		0.16	0.11	-0.17	0.04	0.58	0.07	-0.02	0.15	0.09	-0.12
Net Receivables	0.69	0.76	0.04	0.24	0.5	0.5	-0.45	0.73	0.7	0.63	-0.24	0.3	-0.25	0.45	0.43	0.16		0.59	-0.21	-0.39	-0.01	0.35	0.21	0.07	0.38	-0.35
Inventory	0.7	0.76	0.21	0.52	0.23	0.23	-0.58	0.71	0.62	0.41	-0.2	0.19	-0.19	0.51	0.8	0.11	0.59		-0.23	-0.43	-0.05	0.73	0.21	-0.06	0.76	-0.31
Other Current Assets	-0.02	-0.23	0.16	-0.37	0.09	0.09	0.33	-0.13	-0.11	0.08	0.17	0.05	-0.23	-0.32	-0.2	-0.17	-0.21	-0.23		0.36	-0.26	0.11	-0.21	0.16	-0.02	-0.22
Other Stockholder Equity	0.02	-0.09	0.23	-0.15	0.01	0.01	0.25	-0.27	-0.12	-0.02	0.25	0.37	-0.38	-0.92	-0.08	0.04	-0.39	-0.43	0.36		0.32	-0.11	-0.44	0.75	-0.16	-0.35
Short Term Debt	0.15	0.22	0.04	0.4	-0.14	-0.14	-0.27	-0.19	0.13	-0.06	0.21	0.81	0.31	-0.3	0.35	0.58	-0.01	-0.05	-0.26	0.32		-0.16	-0.3	0.36	-0.12	0.05
Common Stock	0.6	0.59	0.3	0.31	0.23	0.23	-0.38	0.57	0.49	0.37	-0.07	0.1	-0.26	0.18	0.63	0.07	0.35	0.73	0.11	-0.11	-0.16		0.03	0.16	0.99	-0.39
Current Deferred Revenue	0.34	0.24	0.18	-0.39	0.58	0.58	-0.19	0.5	0.27	0.51	-0.97	-0.37	0.04	0.47	-0.08	-0.02	0.21	0.21	-0.21	-0.44	-0.3	0.03		-0.18	0.04	0.03
Accounts Payable	0.5	0.42	0.23	-0.04	0.46	0.46	0.16	0.25	0.49	0.5	-0.07	0.59	-0.61	-0.8	0.2	0.15	0.07	-0.06	0.16	0.75	0.36	0.16	-0.18		0.14	-0.74
Common Stock Total Equity	0.6	0.61	0.26	0.38	0.2	0.2	-0.39	0.58	0.51	0.35	-0.07	0.11	-0.23	0.21	0.66	0.09	0.38	0.76	-0.02	-0.16	-0.12	0.99	0.04	0.14		-0.34
Property Plant And Equipment Gross	-0.69	-0.63	-0.31	-0.08	-0.56	-0.56	0.11	-0.57	-0.66	-0.65	0.15	-0.33	0.73	0.4	-0.41	-0.12	-0.35	-0.31	-0.22	-0.35	0.05	-0.39	0.03	-0.74	-0.34

Click cells to compare fundamentals

Plus Therapeutics Account Relationship Matchups

Plus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.2M	12.1M	22.0M	23.9M	11.4M	10.8M
Short Long Term Debt Total	11.9M	7.0M	7.0M	5.6M	4.2M	4.0M
Total Stockholder Equity	1.2M	3.0M	10.8M	6.4M	(1.3M)	(1.3M)
Net Debt	(5.7M)	(1.4M)	(11.4M)	(12.5M)	(4.4M)	(4.6M)
Cash	17.6M	8.3M	18.4M	18.1M	8.6M	14.2M
Cash And Short Term Investments	17.6M	8.3M	18.4M	18.1M	8.6M	14.1M
Common Stock Shares Outstanding	92.3K	295.2K	805.9K	1.8M	3.1M	3.3M
Liabilities And Stockholders Equity	23.2M	12.1M	22.0M	23.9M	11.4M	10.8M
Non Current Liabilities Total	7.6M	535K	5.3M	5.6M	2.0M	1.9M
Total Liab	22.1M	9.1M	11.1M	17.4M	12.7M	25.2M
Total Current Assets	19.8M	9.2M	19.7M	21.8M	9.8M	17.1M
Other Current Liab	6K	1.3M	1.4M	1.7M	1.9M	2.0M
Total Current Liabilities	14.5M	8.5M	5.9M	11.9M	10.7M	10.5M
Property Plant And Equipment Net	3.0M	2.5M	1.8M	1.6M	1.1M	2.0M
Retained Earnings	(425.3M)	(433.5M)	(446.9M)	(467.2M)	(480.5M)	(456.5M)
Non Current Assets Total	3.4M	2.9M	2.3M	2.1M	1.6M	1.5M
Non Currrent Assets Other	11.7M	72K	16K	12K	32K	30.4K
Net Receivables	233K	1.2M	59K	7K	6.3K	6.0K
Other Current Assets	957K	770K	1.3M	3.7M	1.3M	1.2M
Other Stockholder Equity	426.4M	436.5M	457.7M	473.6M	479.1M	286.3M
Short Term Debt	11.2M	6.5M	1.8M	1.8M	4.1M	4.6M
Common Stock	4K	7K	16K	34K	5K	4.8K
Current Deferred Revenue	1.9M	2.9M	1.3M	1.4M	1.3M	1.2M
Accounts Payable	327K	789K	2.6M	8.4M	4.8M	5.0M
Property Plant And Equipment Gross	3.0M	2.5M	1.8M	1.6M	3.6M	2.1M
Net Tangible Assets	788K	2.6M	10.4M	6.0M	6.9M	3.8M
Capital Surpluse	413.3M	418.4M	426.4M	436.5M	502.0M	424.5M
Property Plant Equipment	2.2M	1.8M	1.8M	1.6M	1.8M	2.0M
Other Assets	72K	652K	16K	12K	10.8K	10.3K
Other Liab	6.9M	7K	1K	1.6M	1.9M	1.4M
Capital Lease Obligations	913K	661K	380K	251K	205K	294.6K
Short Long Term Debt	14.2M	11.1M	6.3M	1.6M	4.0M	5.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC